Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
American Journal of Hematology|June 27, 2015
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalitiesAnne Wanquet, Thomas Prebet, Céline Berthon, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisisDavid Ghez, Jean-Baptiste Micol, Florence Pasquier, et al.
Blood Cancer Journal|June 13, 2024
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA studyPierre Hirsch, Jérôme Lambert, Maxime Bucci, et al.
European Journal of Haematology|September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2013
Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter studyMatthieu Schmidt, Romain Sonneville, David Schnell, et al.
The Journal of Clinical Investigation|March 31, 2015
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemiaKristen Meldi, Tingting Qin, Francesca Buchi, et al.
American Journal of Hematology|June 11, 2013
Outcome of older patients with acute myeloid leukemia in first relapseClémentine Sarkozy, Claude Gardin, Nathalie Gachard, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
Nature Communications|May 19, 2017
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemiaJean-Baptiste Micol, Alessandro Pastore, Daichi Inoue, et al.
Pageof 7